Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Operating Officer | February 15, 2018 | February 23, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director | June 08, 2020 | June 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,612 |
Ending reported balance
After 2018-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 340 · Balance 16,152 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 9,460 · Balance 25,612 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
Quince Therapeutics, Inc.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2030-06-07 | Direct | 11,029 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 11,029 · Balance 11,029 F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2007 Filed Jan 24, 2007 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $65.58 | $0.00 |
DisclosureSEC source: 0001179110-07-001866 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2017-01-22 F1 · derivative.exercise_date: Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012. Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · derivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,670 Underlying: Common Stock · 24,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,264 | $62.06 | $140,503.84 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,400 | $62.05 | $86,870.00 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,518 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,006 | $62.04 | $248,532.24 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,918 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $62.03 | $24,812.00 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,924 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,162 | $62.02 | $196,107.24 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,324 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 900 | $62.01 | $55,809.00 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,486 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,868 | $62.00 | $735,816.00 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,386 Read SEC document |
| August 09, 2006 Filed Aug 11, 2006 19:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 24,000 | $32.02 | $768,480.00 |
DisclosureSEC source: 0001179110-06-016577 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,793 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · derivative · entry 14 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,895 Underlying: Common Stock · 11,793 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested 20% on November 2, 2005, the first anniversary date of the grant. The balance vests every three months thereafter until full vested on November 2, 2009. Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,207 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · derivative · entry 13 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,670 Underlying: Common Stock · 13,207 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 20% on January 26, 2006, the first anniversary date of the grant. The balance vests every three months thereafter until full vested on January 26, 2010. Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,500 | $61.16 | $642,180.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 12 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $61.19 | $12,238.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 11 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,754 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $61.20 | $24,480.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,954 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,800 | $61.18 | $110,124.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,354 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,200 | $61.21 | $195,872.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,154 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $61.22 | $6,122.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,354 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,600 | $61.24 | $342,944.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,454 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $61.25 | $30,625.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,054 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,200 | $61.26 | $134,772.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,554 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $61.23 | $30,615.00 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,754 Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,793 | $35.35 | $416,882.55 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2006 Filed Feb 7, 2006 17:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 13,207 | $32.02 | $422,888.14 |
DisclosureSEC source: 0001179110-06-002999 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-quailified Stock Option (right to buy) · Derivative | 47,172 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · derivative · entry 16 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,688 Underlying: Common Stock · 47,172 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested 20% on November 2, 2005, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,828 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · derivative · entry 15 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,312 Underlying: Common Stock · 2,828 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested 20% on November 2, 2005, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,890 | $60.35 | $1,079,661.50 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 14 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $60.36 | $6,036.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 13 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,144 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,000 | $60.37 | $241,480.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 12 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,244 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $60.38 | $24,152.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 11 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,244 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $60.39 | $18,117.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,644 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $60.40 | $42,280.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,944 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $60.41 | $6,041.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,644 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,100 | $60.42 | $247,722.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,744 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $60.43 | $18,129.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,844 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $60.46 | $6,046.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,144 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 900 | $60.47 | $54,423.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,244 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 21,110 | $60.50 | $1,277,155.00 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,144 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 47,172 | $35.35 | $1,667,530.20 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,254 Read SEC document |
| February 02, 2006 Filed Feb 4, 2006 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,828 | $35.35 | $99,969.80 |
DisclosureSEC source: 0001179110-06-002856 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,082 F2 · balance_after: Amount of Securities Beneficially Owned Following Reported Transaction (s) (Table 1, Col. 5) includes 1,254 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan from December 31, 2004 through December 30, 2005. Read SEC document |
| January 25, 2006 Filed Jan 28, 2006 02:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $58.01 | $0.00 |
DisclosureSEC source: 0001179110-06-002234 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2016-01-25 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 25, 2007, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 25, 2011. Read SEC document |
| January 26, 2005 Filed Jan 28, 2005 21:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 121,877 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-001858 · edgar.xml · derivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,877 Underlying: Common Stock · 121,877 shares Expires 2015-01-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on January 26, 2015. Read SEC document |
| January 26, 2005 Filed Jan 28, 2005 21:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 3,123 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-001858 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,123 Underlying: Common Stock · 3,123 shares Expires 2015-01-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on January 26, 2015. Read SEC document |
| November 02, 2004 Filed Nov 4, 2004 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 235,860 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0001179110-04-020719 · edgar.xml · derivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,860 Underlying: Common Stock · 235,860 shares Expires 2014-11-02 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on November 2, 2005, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on November 2, 2014. Read SEC document |
| November 02, 2004 Filed Nov 4, 2004 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 14,140 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0001179110-04-020719 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,140 Underlying: Common Stock · 14,140 shares Expires 2014-11-02 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on November 2, 2005, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on November 2, 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.